[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA06003748A - Compuestos de lactama condensada. - Google Patents

Compuestos de lactama condensada.

Info

Publication number
MXPA06003748A
MXPA06003748A MXPA06003748A MXPA06003748A MXPA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A MX PA06003748 A MXPA06003748 A MX PA06003748A
Authority
MX
Mexico
Prior art keywords
group
disease
compound
substituents
pharmaceutically
Prior art date
Application number
MXPA06003748A
Other languages
English (en)
Inventor
Masako Hirota
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA06003748A publication Critical patent/MXPA06003748A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion proporciona un compuesto de formula (I) (ver formula (I)): en la que R1 representa un grupo arilo que tiene de 6 a 10 atomos de carbono en el anillo, etc.; R2 representa un atomo de hidrogeno, etc, n representa 0, 1 o 2; dicho grupo heteroarilo esta no sustituido o sustituido y dicho arilo esta sustituido con al menos un sustituyente seleccionado entre el grupo constituido por sustituyentes a; dichos sustituyentes a se seleccionan entre el grupo constituido por atomos de halogeno, grupos alquilo que tienen de 1 a 6 atomos de carbono, etc, o un ester farmaceuticamente aceptable de tal compuesto, o una sal farmaceuticamente aceptable del mismo. estos compuestos son utiles para el tratamiento de estados de enfermedad provocados por la sobreactivacion del receptor de NMDA NR2B tales como dolor, apoplejia, lesion cerebral traumatica, enfermedad de Parkinson, enfermedad de Alzheimer, depresion, ansiedad, migranas o similares, en mamiferos, especialmente seres humanos. Esta invencion tambien proporciona una composicion farmaceutica que comprende el compuesto anterior.
MXPA06003748A 2003-10-08 2004-09-27 Compuestos de lactama condensada. MXPA06003748A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50967003P 2003-10-08 2003-10-08
PCT/IB2004/003125 WO2005035523A1 (en) 2003-10-08 2004-09-27 Fused lactam compounds

Publications (1)

Publication Number Publication Date
MXPA06003748A true MXPA06003748A (es) 2006-06-14

Family

ID=34435007

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06003748A MXPA06003748A (es) 2003-10-08 2004-09-27 Compuestos de lactama condensada.

Country Status (6)

Country Link
EP (1) EP1673367A1 (es)
JP (1) JP2007508288A (es)
BR (1) BRPI0415113A (es)
CA (1) CA2541162A1 (es)
MX (1) MXPA06003748A (es)
WO (1) WO2005035523A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005097782A1 (ja) * 2004-04-07 2007-08-16 協和醗酵工業株式会社 ピペリジン誘導体
PL2599487T3 (pl) 2010-07-30 2015-09-30 Toray Industries Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
US9187506B2 (en) 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US9221796B2 (en) 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
AU2016340239A1 (en) 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146578T3 (es) * 1990-05-10 2000-08-16 Pfizer Indolona neuroprotectora y derivados relacionados.
BR9206272A (pt) * 1991-07-17 1995-04-11 Pfizer Derivados de 2-(4-hidroxipiperidino)-1-alcanol, como agentes anti-isquêmicos.
FR2688504B1 (fr) * 1992-03-13 1995-05-05 Synthelabo Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
ATE150751T1 (de) * 1992-10-30 1997-04-15 Pfizer Neuroprotektive 3,4-dihydro-2(1h)-chinolone
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

Also Published As

Publication number Publication date
EP1673367A1 (en) 2006-06-28
WO2005035523A1 (en) 2005-04-21
BRPI0415113A (pt) 2006-11-28
JP2007508288A (ja) 2007-04-05
CA2541162A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
RS20060143A (en) Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
TW200716528A (en) Cyclopropanecarboxamide derivatives
MY142807A (en) Benzimidazole derivative and use thereof.
HK1031723A1 (en) Cycloalkene derivatives, process for producing thesame, and use.
MXPA06003748A (es) Compuestos de lactama condensada.
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
KR970705542A (ko) 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체(neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
HUP0500201A2 (hu) Policiklusos vegyületek, mint potenciális alfa2-adrenoceptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
NZ515407A (en) 4-Phenyl-pyrimidine derivatives
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
CO5180624A1 (es) Antagonistas muscarinicos
CA2450274A1 (en) Benzoxazepine derivatives and their use as ampa receptor stimulators
DE60000978D1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
KR880005138A (ko) 신규 화합물들
JP2016000700A (ja) ２−アミノ置換ピリジン誘導体
MX9601163A (es) Nuevos compuestos derivados de cromeno.